Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal ...

President-elect Donald Trump's threat to "tariff Denmark at a very high level" if it refuses to give up Greenland could ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Foodpanda, a leading online food delivery platform, has earned the top spot in Bangladesh for its dedication to fostering a ...

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...

Here are 11 healthcare industry lawsuits, settlements and legal developments that Becker's has reported since Jan. 3: ...

Bagsværd, Denmark Friday, January 10, 2025, 11:00 Hrs [IST] ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...